|
|
Blood, 15 September 2004, Vol. 104, No. 6, pp. 1841-1849.
Prepublished online as a Blood First Edition Paper on May 27, 2004; DOI 10.1182/blood-2004-03-1034.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition
Patrick Brown,
Soheil Meshinchi,
Mark Levis,
Todd A. Alonzo,
Robert Gerbing,
Beverly Lange,
Robert Arceci, and
Donald Small
From the Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, and the Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD; the Department of Pediatrics, University of Washington and Clinical Research Division, and the Fred Hutchinson Cancer Research Center, Seattle, WA; the Division of Biostatistics, University of Southern California Keck School of Medicine, Los Angeles, CA; the Children's Oncology Group, Arcadia, CA; and the Division of Oncology, Children's Hospital of Philadelphia, PA.
Pediatric acute myelogenous leukemia (AML) has a poor prognosis, and novel therapies are needed. The FLT3 tyrosine kinase represents a promising target in pediatric AML. FLT3 is constitutively activated either by an internal tandem duplication (ITD) or by a point mutation (PM) in 17% to 24% of pediatric AML cases. Autocrine stimulation of wild-type (WT) FLT3 by coexpressed FLT3 ligand (FL) occurs in many other cases. FLT3/ITD mutations confer a particularly poor prognosis in pediatric AML patients. Inhibitors of FLT3 are being tested in adult AML patients, with promising preliminary results. In this study, cytotoxicity and apoptosis assays were performed on 44 diagnostic pediatric AML blast samples (14 FLT3/WT, 15 FLT3/ITD, 15 FLT3/PM) using CEP-701, a potent and selective FLT3 inhibitor. Pronounced cytotoxicity and induction of apoptosis were observed in a higher percentage of FLT3/ITD samples (93%) than FLT3/PM (27%) or FLT3/WT (29%). The cytotoxicity was greatest in samples with a high FLT3/ITD mutant-to-wild-type allelic ratio. The addition of FL enhanced the survival and augmented the sensitivity to FLT3 inhibition for the CEP-701–responsive subset of FLT3/WT and FLT3/PM samples. Clinical testing of FLT3 inhibitors as molecularly targeted agents for the improvement of outcome of pediatric AML patients is warranted.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. Brown
Adding WT1 to childhood AML alphabet soup
Blood,
June 4, 2009;
113(23):
5696 - 5697.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Gale, C. Green, C. Allen, A. J. Mead, A. K. Burnett, R. K. Hills, D. C. Linch, and on behalf of the Medical Research Council Adult Le
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia
Blood,
March 1, 2008;
111(5):
2776 - 2784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Meshinchi and R. J. Arceci
Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia
Oncologist,
March 1, 2007;
12(3):
341 - 355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Piloto, M. Wright, P. Brown, K.-T. Kim, M. Levis, and D. Small
Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways
Blood,
February 15, 2007;
109(4):
1643 - 1652.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Levis, P. Brown, B. D. Smith, A. Stine, R. Pham, R. Stone, D. DeAngelo, I. Galinsky, F. Giles, E. Estey, et al.
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
Blood,
November 15, 2006;
108(10):
3477 - 3483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Knapper, K. I. Mills, A. F. Gilkes, S. J. Austin, V. Walsh, and A. K. Burnett
The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases
Blood,
November 15, 2006;
108(10):
3494 - 3503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Palmqvist, B. Argiropoulos, N. Pineault, C. Abramovich, L. M. Sly, G. Krystal, A. Wan, and R. K. Humphries
The Flt3 receptor tyrosine kinase collaborates with NUP98-HOX fusions in acute myeloid leukemia
Blood,
August 1, 2006;
108(3):
1030 - 1036.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Stirewalt, K. J. Kopecky, S. Meshinchi, J. H. Engel, E. L. Pogosova-Agadjanyan, J. Linsley, M. L. Slovak, C. L. Willman, and J. P. Radich
Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia
Blood,
May 1, 2006;
107(9):
3724 - 3726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Gale, R. Hills, A. R. Pizzey, P. D. Kottaridis, D. Swirsky, A. F. Gilkes, E. Nugent, K. I. Mills, K. Wheatley, E. Solomon, et al.
Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia
Blood,
December 1, 2005;
106(12):
3768 - 3776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Brown, M. Levis, S. Shurtleff, D. Campana, J. Downing, and D. Small
FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression
Blood,
January 15, 2005;
105(2):
812 - 820.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
